EcoDrugPlus

Protein Tyrosine Kinase 2

Ensembl ID : ENSCSEG00000012851
Gene Symbol: PTK2
1 Cross references
241 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSCSEG00000012197
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSCSEG00000021477
Gene Symbol: PTPRB
4 Cross references
201 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSCSEG00000004604
Gene Symbol: LOC103384848
3 Cross references
197 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSCSEG00000013676
Gene Symbol: LOC103398680
3 Cross references
196 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSCSEG00000008821
Gene Symbol: LOC103385164
3 Cross references
160 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSCSEG00000011427
Gene Symbol: LOC103389897
3 Cross references
265 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSCSEG00000014687
Gene Symbol: LOC103385228
3 Cross references
198 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSCSEG00000015771
Gene Symbol: P2RX3B
1 Cross references
200 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSCSEG00000008813
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSCSEG00000018462
Gene Symbol: P2RY2
3 Cross references
200 Possible Orthologues:

Putative Transcription Factor P65 Homolog

Ensembl ID : ENSCSEG00000019238
Gene Symbol: LOC103385629
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).